How dupilumab affects anxiety and depression in moderate-to-severe atopic dermatitis
Observes mood and quality of life in people with atopic dermatitis taking dupilumab.
Plain-language title generated from the registry record
Registry title: The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Doha, QatarSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with moderate to severe atopic dermatitis who also have signs of anxiety or depression and are starting dupilumab.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe atopic dermatitis, with signs and symptoms of anxiety and/or depression.
- Earlier treatment
- Must start dupilumab within 30 days of enrolment, as decided by the treating doctor. Must not have taken antidepressants or anti-anxiety medicines in the 6 months before enrolment.
Main reasons for not taking part
- Pregnant, breastfeeding, or planning pregnancy in the next 6 months
- Taking part in another trial
- Active infection needing treatment through the body (systemic treatment), or an active parasite infection or high risk of one
- HIV, hepatitis B or C, cancer, or other illnesses at the same time
- Using or planning to use antidepressants or anti-anxiety medicines
Read by machine on 9 November 2026.
Where in Qatar
- Investigational Site: Hamad Medical CorporationDoha, QatarNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sanofi
- Trial code
- NCT07467564
- Record updated
- 28 July 2026
- Original description
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.Read full original descriptionShow less
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
Inclusion: Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression; Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation; Participants and/or their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.
Exclusion: Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses; Participants on antidepressants/anti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants/anti-anxiety. In addition, those who will use antidepressants/anti-anxiety medications throughout the study will be excluded from the analysis; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial; Participants with active chronic or acute infection requiring systemic treatment; Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection; Females who are pregnant, lactating, or planning/intending to be pregnant in the next 6 months; Participants who are participating in another trial.